JEIL PHARMA HOLDINGS INC. stock analysis
Want to see KR:002620 full AI Analyst Report?
JEIL PHARMA HOLDINGS INC. (002620) Stock Price & Analysis
002620 Stock Chart & Stats
- Day’s Range
- KRW 6,690.00 - KRW 6,900.00
- 52-Week Range
- KRW 6,050.00 - KRW 9,850.00
- Previous Close
- KRW 7,000.00
- Volume
- N/A
- Average Volume (3M)
- 5,369
- Market Cap
- KRW 104.39B
- Enterprise Value
- KRW 350.14B
- Total Cash (Recent Filing)
- KRW 87.50B
- Total Debt (Recent Filing)
- KRW 184.74B
- Price to Earnings (P/E)
- 12.4
- Beta
- 0.07
- Next Earnings
- Mar 17, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Dec 29, 2025
- Dividend Yield
- 1.03%
Bulls Say, Bears Say
Bulls Say
Improving Revenue And Gross Margin
The sharp TTM revenue improvement and higher gross margin indicate better commercial traction and product economics. If sustained, this combination can expand the earnings base and provide more resources for reinvestment, although operating-level profitability still needs to follow.
Manageable Leverage
Moderate leverage and a solid equity position provide a relatively stable financial foundation for a specialty pharmaceutical business. This balance-sheet capacity can help the company fund operations and development while reducing the immediate strain associated with heavier debt burdens.
Return To Positive Profitability
The return to positive net income and ROE marks a meaningful improvement from the losses reported during 2022–2024. Continued profitability would strengthen internal funding capacity and signal that recent commercial and margin improvements are becoming more economically productive.
Bears Say
Negative Free Cash Flow
Negative free cash flow shows that the company is not yet consistently self-funding after investment needs. This can limit financial flexibility, increase reliance on external funding, and make reported earnings less useful as an indicator of durable cash-generating power.
Pressed Core Operating Profitability
Negative EBITDA and slightly negative EBIT indicate that core operations remain loss-making even after the return to positive net income. This raises questions about the durability of earnings and means further revenue or gross-margin gains may be needed before operating profits become dependable.
Unstable Profitability And Rising Debt
A history of large annual losses combined with a recent increase in total debt creates execution risk as the company works to stabilize operations. If operating earnings remain weak, additional debt could become more burdensome and reduce future capital-allocation flexibility.
002620 FAQ
What was JEIL PHARMA HOLDINGS INC.’s price range in the past 12 months?
What is JEIL PHARMA HOLDINGS INC.’s market cap?
When is JEIL PHARMA HOLDINGS INC.’s upcoming earnings report date?
How were JEIL PHARMA HOLDINGS INC.’s earnings last quarter?
Is JEIL PHARMA HOLDINGS INC. overvalued?
Does JEIL PHARMA HOLDINGS INC. pay dividends?
What is JEIL PHARMA HOLDINGS INC.’s EPS estimate?
How many shares outstanding does JEIL PHARMA HOLDINGS INC. have?
What happened to JEIL PHARMA HOLDINGS INC.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of JEIL PHARMA HOLDINGS INC.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
JEIL PHARMA HOLDINGS INC.
Jeil Pharma Holdings Inc. is a South Korean pharmaceutical enterprise focused on the production and sale of active pharmaceutical ingredients (APIs), incrementally modified drugs (IMDs), and generic pharmaceuticals. The company's comprehensive API portfolio encompasses a variety of therapeutic areas, including antimicrobials, gastrointestinal remedies, cardiovascular medications, neuropsychiatric treatments, oncology drugs, endocrinology products, urology solutions, antivirals, and antihistamines, in addition to transdermal patch formulations. Furthermore, Jeil Pharma Holdings offers a broad selection of finished dosage forms addressing conditions such as bacterial, fungal, and viral infections; cardiovascular and endocrine disorders; neurological and gastrointestinal ailments; urological and oncological diseases. Its extensive range also features antihistamines, rheumatology, respiratory, otolaryngological, hepatic, and purgative agents. With a global presence, Jeil Pharma Holdings Inc. exports its products to approximately 40 countries, spanning regions like Southeast Asia, Central and South America, and Africa. Founded in 1959, the company's headquarters are situated in Seoul, South Korea.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Seung-Soo Han
- Employees
- 40
- Website
- www.jeilpharm.co.kr
- Address
- 343, Sapyeong-daero, Seoul, SL, 06543, KR
JEIL PHARMA HOLDINGS INC. (002620) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |

